SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of October 2025. The filing, dated October 24, 2025, incorporates by reference a press release issued on October 23, 2025 (Exhibit 99.1). The registrant's principal executive office is located in Mechelen, Belgium. Note: While the request metadata mentions "Lakefront Biotherapeutics NV," the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a vehicle to incorporate a press release by reference and does not contain a financial statement or quantitative data within the provided text.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It references a press release (Exhibit 99.1) for details, but the content of that press release is not included in the provided input text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or descriptions of unusual items. These details are presumed to be contained within the referenced Exhibit 99.1 press release, which is not part of the provided text.
Investor Verification Checklist
- Verify the content of the press release dated October 23, 2025 (Exhibit 99.1), as the filing itself contains no operational or financial details.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
- Review the incorporated Registration Statements on Form S-8 listed in the filing for historical context on equity plans.